文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

利用CD2轴拓宽并增强CAR T细胞疗法的疗效

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.
PubMed 文献 · Blood · 2026-01-01

针对T细胞淋巴瘤和白血病缺乏靶向治疗的问题,研究探索靶向CD2的CAR T细胞(敲除CD2以避免自相残杀)的可行性与疗效。优化后的CD2敲除CART2细胞在体外和体内清除原发CD2+血液肿瘤,但CD2缺失会削弱CAR T细胞功能。研究者开发PD-1:CD2开关受体以挽救CD2信号,改善体内效果。

要点

  • CD2敲除的CART2细胞可有效清除CD2+血液肿瘤,避免自相残杀。
  • CD2缺失会降低CART19对肿瘤抗原的亲和力、共刺激和体内活性。
  • PD-1:CD2开关受体可挽救CD2信号,增强CAR T细胞体内疗效。

核心结论

  • CD2既可作为CAR T细胞治疗T细胞肿瘤的靶点,也是关键的共刺激分子,其信号缺失可通过PD-1:CD2开关受体挽救。

研究设计与样本

  • 临床前研究:使用CRISPR-Cas9生成CD2敲除的CART2细胞,并在体外和体内测试对原发患者来源CD2+血液肿瘤的疗效;利用抗CD19 CART模型研究CD2:CD58轴作用。

主要发现

  • 优化的CD2敲除CART2细胞在体外和体内根除原发患者来源的CD2+血液肿瘤,分泌效应细胞因子并具有足够的增殖能力。
  • CD2缺失通过降低对肿瘤抗原的亲和力、共刺激和最终体内活性,削弱CART19疗效。
  • 肿瘤CD58缺失同样降低CART19疗效。
  • PD-1:CD2开关受体可挽救细胞内CD2信号,尤其在PD-L1 engaged时,改善体内结果。

临床怎么用

  • 靶向CD2的CAR T细胞(敲除CD2)可能为复发/难治T细胞肿瘤提供新治疗选择。
  • 在CAR T细胞中引入PD-1:CD2开关受体可克服CD2信号缺陷,增强疗效。

局限性

  • 研究为临床前阶段,尚未在人体中验证安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with T-cell lymphomas and leukemias have overall poor outcomes because of the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. The development of chimeric antigen receptor (CAR) T cells against T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. We hypothesized that targeting CD2, a pan-T-cell antigen, with anti-CD2 CAR T cells engineered to lack CD2 expression (CART2) would improve manufacturability and preclinical efficacy. Optimized CD2-knockout CART2 cells, generated using CRISPR-Cas9, eradicated primary patient-derived CD2+ hematological neoplasms in vitro and in vivo, secreted effector cytokines, and exhibited adequate proliferative capacity. Nevertheless, CD2 has a key costimulatory function, and its deletion could lead to CAR T-cell dysfunction. Therefore, we tested the role of the CD2:CD58 axis in CAR T cells, using the anti-CD19 CART models. We demonstrate that CD2 loss attenuates CART19 efficacy by reducing avidity for tumor antigen, costimulation, and ultimately in vivo activity. Analogously, we show that tumor CD58 loss reduces CART19 efficacy. To overcome this issue, we developed a novel programmed cell death protein 1 (PD-1):CD2 switch receptor that rescues intracellular CD2 signaling, particularly when programmed death-ligand 1 is engaged, thereby improving in vivo outcomes. Collectively, we studied the role of CD2 both as a target for CAR T-cell therapy and as a critical costimulatory protein, whose signaling can be rescued using the PD-1:CD2 switch receptor. This receptor can be incorporated into CAR T cells and provides an effective strategy to overcome CD2-signaling deficiencies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Carturan A, Angelos MG, Guruprasad P, et al. Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies. Blood. 2026. PMID: 41490267. doi:10.1182/blood.2025031409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。